Slide 1: Q4 2019 Earnings Conference Call
Q4 2019 Earnings Conference Call March 12, 2020 ©2020 ViewRay, Inc. All rights reserved.
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to “
Slide 3: Our Mission: Treat and Prove What Others Can't
Our Mission: Treat and Prove What Others Can’t. ©2020 ViewRay, Inc. All rights reserved. patients treated to date1 systems1 Merit demonstrated in of peer-reviewed journal articles and abstracts1 >8,000 34 Hundreds 3
Slide 4: 2020 Guidance
2020 Guidance ©2020 ViewRay, Inc. All rights reserved. Revenue in the range of $58 - $95 million Cash use in the range of $60 to $80 million Full year impact is uncertain 9 installations planned for 2020 in regions with travel restrictions currently in place REVENUE CASH USE CORONAVIRUS 4
Slide 5: Current Technology for SBRT
Current Technology for SBRT Evidence has shown that ablative dose, 75-100 Gy biological effective doses (BED10), drive favorable outcomes2 Conventional LINACs are limited by dose constraints of surrounding health tissue Clinicians balance the need for ablative doses/tumor coverage vs the risk of tox
Slide 6: MRIdian: No Compromise Necessary
MRIdian: No Compromise Necessary On-table adaptation provides clinicians: Dose escalation in multiple tumor sites to 75-100 Gy BED103 Maintenance of normal organ dose limits or constraints Tighter treatment margins, PTV ≅ CTV3 Real time tumor tracking & gating: Treat the tumor and spare healthy tiss
Slide 7: When 'Good Enough' Is Not Good Enough
When ‘Good Enough’ Is Not Good Enough MRIdian vs. Traditional CT Linac Images courtesy of the Siteman Cancer Center at Washington University School of Medicine MRIdian Market-leading CT LINAC 15 – 30mm Treatment Margins 1 – 5mm Treatment Margins Visibly Different Treatment Margins Software different
Slide 8: Where We Are Today
Where We Are Today: MRIdian has been utilized to treat over 50 ICD cancer types, and its evidence has been documented in hundreds of peer-reviewed journal articles and abstracts ©2020 ViewRay, Inc. All rights reserved. Red Journal6 AUMC treated high-risk lung patients, demonstrating the ability to d
Slide 9: We Safely Deliver 'Ablative' Doses
BED10 in Gy BED (biologically effective dose) calculations involve the use of an accepted radiobiological equation to compare different fractionations regimens by converting them to comparable values for a given tissue of interest. Grade 3+ Toxicity7 Central Lung SBRT Conventional linac @ >100Gy Up
Slide 10: KOL Perspective
Some may prescribe very high dose but allow the target coverage to be potentially horribly low. This is how toxicity might be mitigated but on the other hand they are not giving ablative doses to most or all of the tumor in some cases. I am able to treat with ablative doses to all or nearly all of t
Slide 11: Where We Are Going: Clinical Roadmap
Where We Are Going: Clinical Roadmap clinical collaborators physician-initiated projects in 2020 Multiple tumor sites that prove what others can’t: safely delivering truly ablative doses while reducing toxicity. 26 >30 Plus phase II and III trials in areas such as: Pancreas (our ongoing 13-center st
Slide 12: Strategic Value Yields Economic Value
Strategic Value Yields Economic Value ©2020 ViewRay, Inc. All rights reserved. UP TO 80 INCREMENTAL PATIENTS FOR CANCER PROGRAMS8 + = Powerful Combination ü “…had no other viable options for treatment.” – Dr. Siddiqui, Henry Ford Health Systems ü Multimodality cancer program with MRIdian enables mov
Slide 13: Optimizing Care Delivery
Optimizing Care Delivery Today ©2020 ViewRay, Inc. All rights reserved. Common IMRT Practice: 28 – 44 Fx × 15 min = 420 – 660 min POTENTIAL TO INCREASE PATIENT THROUGHPUT BY 2.3× TO 3.7× Prostate Cancer MRIdian SBRT: 5 Fx with 2 adaptions = 180 min9 13
Slide 14: Economic Value Development
Economic Value Development ©2020 ViewRay, Inc. All rights reserved. Flexible Alternative Acquisition Model Reduce Treatment Times Appropriate and Higher Reimbursement $1 million of COGS reduction over the next three years Sub 30-minute treatment times in prostate and breast Continue to work on diffe
Slide 15: Summary
Summary ©2020 ViewRay, Inc. All rights reserved. ü ü Roadmap to Win: Further Expanding our Clinical, Strategic, and Economic Value Clinical: 30 physician-initiated projects in 2020, plus developing phase II and III studies Strategic and Economic: Sub 30-minute treatment times, flexible alternative a
Slide 16: Q4 Financial Summary
Q4 Financial Summary Total revenue of $16.5 million in the quarter, primarily from three revenue units, including one system upgrade Received 4 MRIdian orders in the quarter totaling approximately $21.2 million Total backlog as of December 31, 2019: $227.3 million Cash and cash equivalents as of Dec
Slide 17: em © VIEW RAY |VISIBLY BETTER’ | qe
em © VIEW RAY |VISIBLY BETTER’ | qe
Slide 18: References
References ©2020 ViewRay, Inc. All rights reserved. 2020 internal and historical company data Hong JC, Ayala-Peacock DN, Lee J, Blackstock AW, Okunieff P, Sung MW, et al. (2018) Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutiona